Adagene Presents Data Demonstrating The Best-In-Class Therapeutic Index For Masked Anti-CTLA-4 SAFEbody ADG126 At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
Adagene Inc. (NASDAQ:ADAG) presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data demonstrated that ADG126 is effective at targeting CTLA-4 within the tumor microenvironment (TME), resulting in a wider therapeutic index (TI) compared to ipilimumab when combined with anti-PD-1 therapies. The company also reported a clinical case example showing that ADG126 plus pembrolizumab resulted in a confirmed partial response in a patient with advanced/metastatic MSS CRC.
November 03, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adagene's new data on ADG126 demonstrates its potential as a best-in-class CTLA-4 therapy. This could positively impact the company's stock in the short term.
The new data presented by Adagene demonstrates the effectiveness of its ADG126 therapy. This positive news could increase investor confidence in the company, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100